Global Sacroiliitis Treatment Market

Sacroiliitis Treatment Comprehensive Study by Type (Medication, Pain relievers, Muscle relaxants, TNF inhibitors, Joint Injections, Radiofrequency denervation, Electrical stimulation, Joint fusion), Application (Hospitals, Clinics, Others), Diagnosis (Imaging Tests, Anesthetic Injections) Players and Region - Global Market Outlook to 2026

Sacroiliitis Treatment Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
What is Sacroiliitis Treatment Market?

Sacroiliitis is an inflammation of one or both of your sacroiliac joints that can cause pain in the lower back or buttocks. This is caused due to traumatic injury, arthritis, pregnancy or infection. It can be difficult to diagnose since many other conditions cause pain in the same locations. These symptoms can be aggravated by prolonged standing, bearing more weight on one leg than the other, stair climbing, running and taking large strides. Sacroiliitis treatment may involve physical therapy and medications depend on the type of sacroiliitis.

The market study is being classified by Type (Medication, Pain relievers, Muscle relaxants, TNF inhibitors, Joint Injections, Radiofrequency denervation, Electrical stimulation and Joint fusion), by Application (Hospitals, Clinics and Others) and major geographies with country level break-up.

Pfizer Inc. (United States), Allergan, Inc. (Ireland), Ipsen Group (France), Teva Pharmaceuticals (Israel), Novartis International AG (Switzerland), Johnson & Johnson (United States), STEROID S.p.A. (Italy), Sanofi (France), Bioventus (United States), Salix Pharmaceuticals (United States), Smith & Nephew Plc (United Kingdom) and Globus Medical Inc (United States) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are SI-BONE (United States), NuTech Medical (United States), Medacta Group (Switzerland) and Aspen Medical Products, LLC (United States).

The companies are exploring the market by adopting expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions across the globe to gain a competitive advantage through combined collaborations. Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Sacroiliitis Treatment market throughout the predicted period.

Segment Analysis
Analyst at AMA have segmented the market study of Global Sacroiliitis Treatment market by Type, Application and Region.

On the basis of geography, the market of Sacroiliitis Treatment has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Market Drivers
  • Increased Prevalence of Arthritis among People
  • Development of New Diagnostic Centres and Hospitals

Market Trend
  • Rise in the Healthcare Infrsasture in Developing Countries
  • Growing Awareness about Sacroiliitis Treatment

Restraints
  • Difficulties Associated with Diagnosis of Sacroiliitis

Opportunities
  • Growth in the Geriatric Population Worldwide
  • Growing Healthcare Industry Worldwide

Challenges
  • Stringent Rules and Regulations





Key Target Audience
Sacroiliitis Treatment Providers, Emerging Companies, Research Professionals and End-users

Report Objectives / Segmentation Covered

By Type
  • Medication
  • Pain relievers
  • Muscle relaxants
  • TNF inhibitors
  • Joint Injections
  • Radiofrequency denervation
  • Electrical stimulation
  • Joint fusion
By Application
  • Hospitals
  • Clinics
  • Others
By Diagnosis
  • Imaging Tests
  • Anesthetic Injections

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increased Prevalence of Arthritis among People
      • 3.2.2. Development of New Diagnostic Centres and Hospitals
    • 3.3. Market Challenges
      • 3.3.1. Stringent Rules and Regulations
    • 3.4. Market Trends
      • 3.4.1. Rise in the Healthcare Infrsasture in Developing Countries
      • 3.4.2. Growing Awareness about Sacroiliitis Treatment
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Sacroiliitis Treatment, by Type, Application, Diagnosis and Region (value) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Sacroiliitis Treatment (Value)
      • 5.2.1. Global Sacroiliitis Treatment by: Type (Value)
        • 5.2.1.1. Medication
        • 5.2.1.2. Pain relievers
        • 5.2.1.3. Muscle relaxants
        • 5.2.1.4. TNF inhibitors
        • 5.2.1.5. Joint Injections
        • 5.2.1.6. Radiofrequency denervation
        • 5.2.1.7. Electrical stimulation
        • 5.2.1.8. Joint fusion
      • 5.2.2. Global Sacroiliitis Treatment by: Application (Value)
        • 5.2.2.1. Hospitals
        • 5.2.2.2. Clinics
        • 5.2.2.3. Others
      • 5.2.3. Global Sacroiliitis Treatment by: Diagnosis (Value)
        • 5.2.3.1. Imaging Tests
        • 5.2.3.2. Anesthetic Injections
      • 5.2.4. Global Sacroiliitis Treatment Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
  • 6. Sacroiliitis Treatment: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Pfizer Inc. (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Allergan, Inc. (Ireland)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Ipsen Group (France)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Teva Pharmaceuticals (Israel)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Novartis International AG (Switzerland)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Johnson & Johnson (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. STEROID S.p.A. (Italy)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Sanofi (France)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Bioventus (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Salix Pharmaceuticals (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Smith & Nephew Plc (United Kingdom)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
      • 6.4.12. Globus Medical Inc (United States)
        • 6.4.12.1. Business Overview
        • 6.4.12.2. Products/Services Offerings
        • 6.4.12.3. Financial Analysis
        • 6.4.12.4. SWOT Analysis
  • 7. Global Sacroiliitis Treatment Sale, by Type, Application, Diagnosis and Region (value) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Sacroiliitis Treatment (Value)
      • 7.2.1. Global Sacroiliitis Treatment by: Type (Value)
        • 7.2.1.1. Medication
        • 7.2.1.2. Pain relievers
        • 7.2.1.3. Muscle relaxants
        • 7.2.1.4. TNF inhibitors
        • 7.2.1.5. Joint Injections
        • 7.2.1.6. Radiofrequency denervation
        • 7.2.1.7. Electrical stimulation
        • 7.2.1.8. Joint fusion
      • 7.2.2. Global Sacroiliitis Treatment by: Application (Value)
        • 7.2.2.1. Hospitals
        • 7.2.2.2. Clinics
        • 7.2.2.3. Others
      • 7.2.3. Global Sacroiliitis Treatment by: Diagnosis (Value)
        • 7.2.3.1. Imaging Tests
        • 7.2.3.2. Anesthetic Injections
      • 7.2.4. Global Sacroiliitis Treatment Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Sacroiliitis Treatment: by Type(USD Million)
  • Table 2. Sacroiliitis Treatment Medication , by Region USD Million (2015-2020)
  • Table 3. Sacroiliitis Treatment Pain relievers , by Region USD Million (2015-2020)
  • Table 4. Sacroiliitis Treatment Muscle relaxants , by Region USD Million (2015-2020)
  • Table 5. Sacroiliitis Treatment TNF inhibitors , by Region USD Million (2015-2020)
  • Table 6. Sacroiliitis Treatment Joint Injections , by Region USD Million (2015-2020)
  • Table 7. Sacroiliitis Treatment Radiofrequency denervation , by Region USD Million (2015-2020)
  • Table 8. Sacroiliitis Treatment Electrical stimulation , by Region USD Million (2015-2020)
  • Table 9. Sacroiliitis Treatment Joint fusion , by Region USD Million (2015-2020)
  • Table 10. Sacroiliitis Treatment: by Application(USD Million)
  • Table 11. Sacroiliitis Treatment Hospitals , by Region USD Million (2015-2020)
  • Table 12. Sacroiliitis Treatment Clinics , by Region USD Million (2015-2020)
  • Table 13. Sacroiliitis Treatment Others , by Region USD Million (2015-2020)
  • Table 14. Sacroiliitis Treatment: by Diagnosis(USD Million)
  • Table 15. Sacroiliitis Treatment Imaging Tests , by Region USD Million (2015-2020)
  • Table 16. Sacroiliitis Treatment Anesthetic Injections , by Region USD Million (2015-2020)
  • Table 17. South America Sacroiliitis Treatment, by Country USD Million (2015-2020)
  • Table 18. South America Sacroiliitis Treatment, by Type USD Million (2015-2020)
  • Table 19. South America Sacroiliitis Treatment, by Application USD Million (2015-2020)
  • Table 20. South America Sacroiliitis Treatment, by Diagnosis USD Million (2015-2020)
  • Table 21. Brazil Sacroiliitis Treatment, by Type USD Million (2015-2020)
  • Table 22. Brazil Sacroiliitis Treatment, by Application USD Million (2015-2020)
  • Table 23. Brazil Sacroiliitis Treatment, by Diagnosis USD Million (2015-2020)
  • Table 24. Argentina Sacroiliitis Treatment, by Type USD Million (2015-2020)
  • Table 25. Argentina Sacroiliitis Treatment, by Application USD Million (2015-2020)
  • Table 26. Argentina Sacroiliitis Treatment, by Diagnosis USD Million (2015-2020)
  • Table 27. Rest of South America Sacroiliitis Treatment, by Type USD Million (2015-2020)
  • Table 28. Rest of South America Sacroiliitis Treatment, by Application USD Million (2015-2020)
  • Table 29. Rest of South America Sacroiliitis Treatment, by Diagnosis USD Million (2015-2020)
  • Table 30. Asia Pacific Sacroiliitis Treatment, by Country USD Million (2015-2020)
  • Table 31. Asia Pacific Sacroiliitis Treatment, by Type USD Million (2015-2020)
  • Table 32. Asia Pacific Sacroiliitis Treatment, by Application USD Million (2015-2020)
  • Table 33. Asia Pacific Sacroiliitis Treatment, by Diagnosis USD Million (2015-2020)
  • Table 34. China Sacroiliitis Treatment, by Type USD Million (2015-2020)
  • Table 35. China Sacroiliitis Treatment, by Application USD Million (2015-2020)
  • Table 36. China Sacroiliitis Treatment, by Diagnosis USD Million (2015-2020)
  • Table 37. Japan Sacroiliitis Treatment, by Type USD Million (2015-2020)
  • Table 38. Japan Sacroiliitis Treatment, by Application USD Million (2015-2020)
  • Table 39. Japan Sacroiliitis Treatment, by Diagnosis USD Million (2015-2020)
  • Table 40. India Sacroiliitis Treatment, by Type USD Million (2015-2020)
  • Table 41. India Sacroiliitis Treatment, by Application USD Million (2015-2020)
  • Table 42. India Sacroiliitis Treatment, by Diagnosis USD Million (2015-2020)
  • Table 43. South Korea Sacroiliitis Treatment, by Type USD Million (2015-2020)
  • Table 44. South Korea Sacroiliitis Treatment, by Application USD Million (2015-2020)
  • Table 45. South Korea Sacroiliitis Treatment, by Diagnosis USD Million (2015-2020)
  • Table 46. Taiwan Sacroiliitis Treatment, by Type USD Million (2015-2020)
  • Table 47. Taiwan Sacroiliitis Treatment, by Application USD Million (2015-2020)
  • Table 48. Taiwan Sacroiliitis Treatment, by Diagnosis USD Million (2015-2020)
  • Table 49. Australia Sacroiliitis Treatment, by Type USD Million (2015-2020)
  • Table 50. Australia Sacroiliitis Treatment, by Application USD Million (2015-2020)
  • Table 51. Australia Sacroiliitis Treatment, by Diagnosis USD Million (2015-2020)
  • Table 52. Rest of Asia-Pacific Sacroiliitis Treatment, by Type USD Million (2015-2020)
  • Table 53. Rest of Asia-Pacific Sacroiliitis Treatment, by Application USD Million (2015-2020)
  • Table 54. Rest of Asia-Pacific Sacroiliitis Treatment, by Diagnosis USD Million (2015-2020)
  • Table 55. Europe Sacroiliitis Treatment, by Country USD Million (2015-2020)
  • Table 56. Europe Sacroiliitis Treatment, by Type USD Million (2015-2020)
  • Table 57. Europe Sacroiliitis Treatment, by Application USD Million (2015-2020)
  • Table 58. Europe Sacroiliitis Treatment, by Diagnosis USD Million (2015-2020)
  • Table 59. Germany Sacroiliitis Treatment, by Type USD Million (2015-2020)
  • Table 60. Germany Sacroiliitis Treatment, by Application USD Million (2015-2020)
  • Table 61. Germany Sacroiliitis Treatment, by Diagnosis USD Million (2015-2020)
  • Table 62. France Sacroiliitis Treatment, by Type USD Million (2015-2020)
  • Table 63. France Sacroiliitis Treatment, by Application USD Million (2015-2020)
  • Table 64. France Sacroiliitis Treatment, by Diagnosis USD Million (2015-2020)
  • Table 65. Italy Sacroiliitis Treatment, by Type USD Million (2015-2020)
  • Table 66. Italy Sacroiliitis Treatment, by Application USD Million (2015-2020)
  • Table 67. Italy Sacroiliitis Treatment, by Diagnosis USD Million (2015-2020)
  • Table 68. United Kingdom Sacroiliitis Treatment, by Type USD Million (2015-2020)
  • Table 69. United Kingdom Sacroiliitis Treatment, by Application USD Million (2015-2020)
  • Table 70. United Kingdom Sacroiliitis Treatment, by Diagnosis USD Million (2015-2020)
  • Table 71. Netherlands Sacroiliitis Treatment, by Type USD Million (2015-2020)
  • Table 72. Netherlands Sacroiliitis Treatment, by Application USD Million (2015-2020)
  • Table 73. Netherlands Sacroiliitis Treatment, by Diagnosis USD Million (2015-2020)
  • Table 74. Rest of Europe Sacroiliitis Treatment, by Type USD Million (2015-2020)
  • Table 75. Rest of Europe Sacroiliitis Treatment, by Application USD Million (2015-2020)
  • Table 76. Rest of Europe Sacroiliitis Treatment, by Diagnosis USD Million (2015-2020)
  • Table 77. MEA Sacroiliitis Treatment, by Country USD Million (2015-2020)
  • Table 78. MEA Sacroiliitis Treatment, by Type USD Million (2015-2020)
  • Table 79. MEA Sacroiliitis Treatment, by Application USD Million (2015-2020)
  • Table 80. MEA Sacroiliitis Treatment, by Diagnosis USD Million (2015-2020)
  • Table 81. Middle East Sacroiliitis Treatment, by Type USD Million (2015-2020)
  • Table 82. Middle East Sacroiliitis Treatment, by Application USD Million (2015-2020)
  • Table 83. Middle East Sacroiliitis Treatment, by Diagnosis USD Million (2015-2020)
  • Table 84. Africa Sacroiliitis Treatment, by Type USD Million (2015-2020)
  • Table 85. Africa Sacroiliitis Treatment, by Application USD Million (2015-2020)
  • Table 86. Africa Sacroiliitis Treatment, by Diagnosis USD Million (2015-2020)
  • Table 87. North America Sacroiliitis Treatment, by Country USD Million (2015-2020)
  • Table 88. North America Sacroiliitis Treatment, by Type USD Million (2015-2020)
  • Table 89. North America Sacroiliitis Treatment, by Application USD Million (2015-2020)
  • Table 90. North America Sacroiliitis Treatment, by Diagnosis USD Million (2015-2020)
  • Table 91. United States Sacroiliitis Treatment, by Type USD Million (2015-2020)
  • Table 92. United States Sacroiliitis Treatment, by Application USD Million (2015-2020)
  • Table 93. United States Sacroiliitis Treatment, by Diagnosis USD Million (2015-2020)
  • Table 94. Canada Sacroiliitis Treatment, by Type USD Million (2015-2020)
  • Table 95. Canada Sacroiliitis Treatment, by Application USD Million (2015-2020)
  • Table 96. Canada Sacroiliitis Treatment, by Diagnosis USD Million (2015-2020)
  • Table 97. Mexico Sacroiliitis Treatment, by Type USD Million (2015-2020)
  • Table 98. Mexico Sacroiliitis Treatment, by Application USD Million (2015-2020)
  • Table 99. Mexico Sacroiliitis Treatment, by Diagnosis USD Million (2015-2020)
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Company Basic Information, Sales Area and Its Competitors
  • Table 107. Company Basic Information, Sales Area and Its Competitors
  • Table 108. Company Basic Information, Sales Area and Its Competitors
  • Table 109. Company Basic Information, Sales Area and Its Competitors
  • Table 110. Company Basic Information, Sales Area and Its Competitors
  • Table 111. Company Basic Information, Sales Area and Its Competitors
  • Table 112. Sacroiliitis Treatment: by Type(USD Million)
  • Table 113. Sacroiliitis Treatment Medication , by Region USD Million (2021-2026)
  • Table 114. Sacroiliitis Treatment Pain relievers , by Region USD Million (2021-2026)
  • Table 115. Sacroiliitis Treatment Muscle relaxants , by Region USD Million (2021-2026)
  • Table 116. Sacroiliitis Treatment TNF inhibitors , by Region USD Million (2021-2026)
  • Table 117. Sacroiliitis Treatment Joint Injections , by Region USD Million (2021-2026)
  • Table 118. Sacroiliitis Treatment Radiofrequency denervation , by Region USD Million (2021-2026)
  • Table 119. Sacroiliitis Treatment Electrical stimulation , by Region USD Million (2021-2026)
  • Table 120. Sacroiliitis Treatment Joint fusion , by Region USD Million (2021-2026)
  • Table 121. Sacroiliitis Treatment: by Application(USD Million)
  • Table 122. Sacroiliitis Treatment Hospitals , by Region USD Million (2021-2026)
  • Table 123. Sacroiliitis Treatment Clinics , by Region USD Million (2021-2026)
  • Table 124. Sacroiliitis Treatment Others , by Region USD Million (2021-2026)
  • Table 125. Sacroiliitis Treatment: by Diagnosis(USD Million)
  • Table 126. Sacroiliitis Treatment Imaging Tests , by Region USD Million (2021-2026)
  • Table 127. Sacroiliitis Treatment Anesthetic Injections , by Region USD Million (2021-2026)
  • Table 128. South America Sacroiliitis Treatment, by Country USD Million (2021-2026)
  • Table 129. South America Sacroiliitis Treatment, by Type USD Million (2021-2026)
  • Table 130. South America Sacroiliitis Treatment, by Application USD Million (2021-2026)
  • Table 131. South America Sacroiliitis Treatment, by Diagnosis USD Million (2021-2026)
  • Table 132. Brazil Sacroiliitis Treatment, by Type USD Million (2021-2026)
  • Table 133. Brazil Sacroiliitis Treatment, by Application USD Million (2021-2026)
  • Table 134. Brazil Sacroiliitis Treatment, by Diagnosis USD Million (2021-2026)
  • Table 135. Argentina Sacroiliitis Treatment, by Type USD Million (2021-2026)
  • Table 136. Argentina Sacroiliitis Treatment, by Application USD Million (2021-2026)
  • Table 137. Argentina Sacroiliitis Treatment, by Diagnosis USD Million (2021-2026)
  • Table 138. Rest of South America Sacroiliitis Treatment, by Type USD Million (2021-2026)
  • Table 139. Rest of South America Sacroiliitis Treatment, by Application USD Million (2021-2026)
  • Table 140. Rest of South America Sacroiliitis Treatment, by Diagnosis USD Million (2021-2026)
  • Table 141. Asia Pacific Sacroiliitis Treatment, by Country USD Million (2021-2026)
  • Table 142. Asia Pacific Sacroiliitis Treatment, by Type USD Million (2021-2026)
  • Table 143. Asia Pacific Sacroiliitis Treatment, by Application USD Million (2021-2026)
  • Table 144. Asia Pacific Sacroiliitis Treatment, by Diagnosis USD Million (2021-2026)
  • Table 145. China Sacroiliitis Treatment, by Type USD Million (2021-2026)
  • Table 146. China Sacroiliitis Treatment, by Application USD Million (2021-2026)
  • Table 147. China Sacroiliitis Treatment, by Diagnosis USD Million (2021-2026)
  • Table 148. Japan Sacroiliitis Treatment, by Type USD Million (2021-2026)
  • Table 149. Japan Sacroiliitis Treatment, by Application USD Million (2021-2026)
  • Table 150. Japan Sacroiliitis Treatment, by Diagnosis USD Million (2021-2026)
  • Table 151. India Sacroiliitis Treatment, by Type USD Million (2021-2026)
  • Table 152. India Sacroiliitis Treatment, by Application USD Million (2021-2026)
  • Table 153. India Sacroiliitis Treatment, by Diagnosis USD Million (2021-2026)
  • Table 154. South Korea Sacroiliitis Treatment, by Type USD Million (2021-2026)
  • Table 155. South Korea Sacroiliitis Treatment, by Application USD Million (2021-2026)
  • Table 156. South Korea Sacroiliitis Treatment, by Diagnosis USD Million (2021-2026)
  • Table 157. Taiwan Sacroiliitis Treatment, by Type USD Million (2021-2026)
  • Table 158. Taiwan Sacroiliitis Treatment, by Application USD Million (2021-2026)
  • Table 159. Taiwan Sacroiliitis Treatment, by Diagnosis USD Million (2021-2026)
  • Table 160. Australia Sacroiliitis Treatment, by Type USD Million (2021-2026)
  • Table 161. Australia Sacroiliitis Treatment, by Application USD Million (2021-2026)
  • Table 162. Australia Sacroiliitis Treatment, by Diagnosis USD Million (2021-2026)
  • Table 163. Rest of Asia-Pacific Sacroiliitis Treatment, by Type USD Million (2021-2026)
  • Table 164. Rest of Asia-Pacific Sacroiliitis Treatment, by Application USD Million (2021-2026)
  • Table 165. Rest of Asia-Pacific Sacroiliitis Treatment, by Diagnosis USD Million (2021-2026)
  • Table 166. Europe Sacroiliitis Treatment, by Country USD Million (2021-2026)
  • Table 167. Europe Sacroiliitis Treatment, by Type USD Million (2021-2026)
  • Table 168. Europe Sacroiliitis Treatment, by Application USD Million (2021-2026)
  • Table 169. Europe Sacroiliitis Treatment, by Diagnosis USD Million (2021-2026)
  • Table 170. Germany Sacroiliitis Treatment, by Type USD Million (2021-2026)
  • Table 171. Germany Sacroiliitis Treatment, by Application USD Million (2021-2026)
  • Table 172. Germany Sacroiliitis Treatment, by Diagnosis USD Million (2021-2026)
  • Table 173. France Sacroiliitis Treatment, by Type USD Million (2021-2026)
  • Table 174. France Sacroiliitis Treatment, by Application USD Million (2021-2026)
  • Table 175. France Sacroiliitis Treatment, by Diagnosis USD Million (2021-2026)
  • Table 176. Italy Sacroiliitis Treatment, by Type USD Million (2021-2026)
  • Table 177. Italy Sacroiliitis Treatment, by Application USD Million (2021-2026)
  • Table 178. Italy Sacroiliitis Treatment, by Diagnosis USD Million (2021-2026)
  • Table 179. United Kingdom Sacroiliitis Treatment, by Type USD Million (2021-2026)
  • Table 180. United Kingdom Sacroiliitis Treatment, by Application USD Million (2021-2026)
  • Table 181. United Kingdom Sacroiliitis Treatment, by Diagnosis USD Million (2021-2026)
  • Table 182. Netherlands Sacroiliitis Treatment, by Type USD Million (2021-2026)
  • Table 183. Netherlands Sacroiliitis Treatment, by Application USD Million (2021-2026)
  • Table 184. Netherlands Sacroiliitis Treatment, by Diagnosis USD Million (2021-2026)
  • Table 185. Rest of Europe Sacroiliitis Treatment, by Type USD Million (2021-2026)
  • Table 186. Rest of Europe Sacroiliitis Treatment, by Application USD Million (2021-2026)
  • Table 187. Rest of Europe Sacroiliitis Treatment, by Diagnosis USD Million (2021-2026)
  • Table 188. MEA Sacroiliitis Treatment, by Country USD Million (2021-2026)
  • Table 189. MEA Sacroiliitis Treatment, by Type USD Million (2021-2026)
  • Table 190. MEA Sacroiliitis Treatment, by Application USD Million (2021-2026)
  • Table 191. MEA Sacroiliitis Treatment, by Diagnosis USD Million (2021-2026)
  • Table 192. Middle East Sacroiliitis Treatment, by Type USD Million (2021-2026)
  • Table 193. Middle East Sacroiliitis Treatment, by Application USD Million (2021-2026)
  • Table 194. Middle East Sacroiliitis Treatment, by Diagnosis USD Million (2021-2026)
  • Table 195. Africa Sacroiliitis Treatment, by Type USD Million (2021-2026)
  • Table 196. Africa Sacroiliitis Treatment, by Application USD Million (2021-2026)
  • Table 197. Africa Sacroiliitis Treatment, by Diagnosis USD Million (2021-2026)
  • Table 198. North America Sacroiliitis Treatment, by Country USD Million (2021-2026)
  • Table 199. North America Sacroiliitis Treatment, by Type USD Million (2021-2026)
  • Table 200. North America Sacroiliitis Treatment, by Application USD Million (2021-2026)
  • Table 201. North America Sacroiliitis Treatment, by Diagnosis USD Million (2021-2026)
  • Table 202. United States Sacroiliitis Treatment, by Type USD Million (2021-2026)
  • Table 203. United States Sacroiliitis Treatment, by Application USD Million (2021-2026)
  • Table 204. United States Sacroiliitis Treatment, by Diagnosis USD Million (2021-2026)
  • Table 205. Canada Sacroiliitis Treatment, by Type USD Million (2021-2026)
  • Table 206. Canada Sacroiliitis Treatment, by Application USD Million (2021-2026)
  • Table 207. Canada Sacroiliitis Treatment, by Diagnosis USD Million (2021-2026)
  • Table 208. Mexico Sacroiliitis Treatment, by Type USD Million (2021-2026)
  • Table 209. Mexico Sacroiliitis Treatment, by Application USD Million (2021-2026)
  • Table 210. Mexico Sacroiliitis Treatment, by Diagnosis USD Million (2021-2026)
  • Table 211. Research Programs/Design for This Report
  • Table 212. Key Data Information from Secondary Sources
  • Table 213. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Sacroiliitis Treatment: by Type USD Million (2015-2020)
  • Figure 5. Global Sacroiliitis Treatment: by Application USD Million (2015-2020)
  • Figure 6. Global Sacroiliitis Treatment: by Diagnosis USD Million (2015-2020)
  • Figure 7. South America Sacroiliitis Treatment Share (%), by Country
  • Figure 8. Asia Pacific Sacroiliitis Treatment Share (%), by Country
  • Figure 9. Europe Sacroiliitis Treatment Share (%), by Country
  • Figure 10. MEA Sacroiliitis Treatment Share (%), by Country
  • Figure 11. North America Sacroiliitis Treatment Share (%), by Country
  • Figure 12. Global Sacroiliitis Treatment share by Players 2020 (%)
  • Figure 13. Global Sacroiliitis Treatment share by Players (Top 3) 2020(%)
  • Figure 14. Global Sacroiliitis Treatment share by Players (Top 5) 2020(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 17. Pfizer Inc. (United States) Revenue: by Geography 2020
  • Figure 18. Allergan, Inc. (Ireland) Revenue, Net Income and Gross profit
  • Figure 19. Allergan, Inc. (Ireland) Revenue: by Geography 2020
  • Figure 20. Ipsen Group (France) Revenue, Net Income and Gross profit
  • Figure 21. Ipsen Group (France) Revenue: by Geography 2020
  • Figure 22. Teva Pharmaceuticals (Israel) Revenue, Net Income and Gross profit
  • Figure 23. Teva Pharmaceuticals (Israel) Revenue: by Geography 2020
  • Figure 24. Novartis International AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 25. Novartis International AG (Switzerland) Revenue: by Geography 2020
  • Figure 26. Johnson & Johnson (United States) Revenue, Net Income and Gross profit
  • Figure 27. Johnson & Johnson (United States) Revenue: by Geography 2020
  • Figure 28. STEROID S.p.A. (Italy) Revenue, Net Income and Gross profit
  • Figure 29. STEROID S.p.A. (Italy) Revenue: by Geography 2020
  • Figure 30. Sanofi (France) Revenue, Net Income and Gross profit
  • Figure 31. Sanofi (France) Revenue: by Geography 2020
  • Figure 32. Bioventus (United States) Revenue, Net Income and Gross profit
  • Figure 33. Bioventus (United States) Revenue: by Geography 2020
  • Figure 34. Salix Pharmaceuticals (United States) Revenue, Net Income and Gross profit
  • Figure 35. Salix Pharmaceuticals (United States) Revenue: by Geography 2020
  • Figure 36. Smith & Nephew Plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 37. Smith & Nephew Plc (United Kingdom) Revenue: by Geography 2020
  • Figure 38. Globus Medical Inc (United States) Revenue, Net Income and Gross profit
  • Figure 39. Globus Medical Inc (United States) Revenue: by Geography 2020
  • Figure 40. Global Sacroiliitis Treatment: by Type USD Million (2021-2026)
  • Figure 41. Global Sacroiliitis Treatment: by Application USD Million (2021-2026)
  • Figure 42. Global Sacroiliitis Treatment: by Diagnosis USD Million (2021-2026)
  • Figure 43. South America Sacroiliitis Treatment Share (%), by Country
  • Figure 44. Asia Pacific Sacroiliitis Treatment Share (%), by Country
  • Figure 45. Europe Sacroiliitis Treatment Share (%), by Country
  • Figure 46. MEA Sacroiliitis Treatment Share (%), by Country
  • Figure 47. North America Sacroiliitis Treatment Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Pfizer Inc. (United States)
  • Allergan, Inc. (Ireland)
  • Ipsen Group (France)
  • Teva Pharmaceuticals (Israel)
  • Novartis International AG (Switzerland)
  • Johnson & Johnson (United States)
  • STEROID S.p.A. (Italy)
  • Sanofi (France)
  • Bioventus (United States)
  • Salix Pharmaceuticals (United States)
  • Smith & Nephew Plc (United Kingdom)
  • Globus Medical Inc (United States)
Additional players considered in the study are as follows:
SI-BONE (United States) , NuTech Medical (United States) , Medacta Group (Switzerland) , Aspen Medical Products, LLC (United States)
Select User Access Type

Key Highlights of Report


Apr 2021 239 Pages 81 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Sacroiliitis Treatment Market Quantitative research analysis
Global Sacroiliitis Treatment Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

"Increased Prevalence of Arthritis among People " is seen as one of major growth factors of Sacroiliitis Treatment Market in years to come.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.

Know More About Global Sacroiliitis Treatment Market Report?

Have a Query? Click Here

Other Related Reports

Leishmaniasis Treatment Comprehensive Study by Application (Cutaneous leishmaniasis, Visceral leishmaniasis, Mucocutaneous leishmaniasis), Drug Type (Pentavalent antimonials (Sodium stibogluconate, S...
$ 3750
Phage Therapy Comprehensive Study by Application (Diagnostic, Antimicrobial Drug Discovery, Veterinary Medicines, Others), Route of Administration (Oral, Topical), Targeted Bacteria (Escherichia coli...
$ 3750
Respiratory Virus Infection Drugs Comprehensive Study by Type (Penicillin VK, Amoxicillin, Penicillin G benzathine, Cefadroxil, Erythromycin, Amoxicillin and clavulanate, Others), Disease Type (COVID...
$ 3750
Behcet's Disease Treatment Comprehensive Study by Type (Anti-inflammatory Medications (Ibuprofen), Topical Ointments (Corticosteroid), Immunosuppressive Medications), Route of Administration (Oral, I...
$ 3750
Wolff Parkinson White Syndrome Treatment Comprehensive Study by Type (Type A, Type B), Treatment (Drugs {Anti-Arrhythmic, Beta-Blockers, Others}, Cardioversion, Radiofrequency Catheter Ablation, Surg...
$ 3750
Transurethral Resection of the Prostate (TURP) Comprehensive Study by Application (Hospital, Clinic, Laboratory), Devices (Resectoscopes, Catheters and Resectoscopes Electrodes, Monopolar Electrodes...
$ 3650